No, it is only effective in postmenopausal women whose ovaries have stopped functioning. In premenopausal women, it can cause a compensatory increase in ovarian estrogen production.

Estrogen plays a key role in maintaining joint tissues and bone mineral density. The profound estrogen suppression caused by Anastrozole frequently leads to arthralgia and bone thinning.

A Dual-Energy X-ray Absorptiometry (DEXA) bone density scan should be performed at baseline and periodically to monitor for osteoporosis.

The standard dose is 1mg taken once daily, with or without food, at the same time each day.

In early hormone-receptor-positive breast cancer, adjuvant therapy is typically prescribed for a continuous duration of 5 years to minimize recurrence risks.

It can cause mild estrogen-deprivation hair thinning or male-pattern hair loss, but rarely results in complete alopecia.

No, estrogen therapies will directly counteract the mechanism of Anastrozole and potentially fuel breast cancer cell growth.

No, aromatase inhibitors carry a significantly lower risk of thromboembolic events and endometrial cancer compared to Tamoxifen.

Anastrozole can elevate blood cholesterol levels, so lipid profiles should be checked regularly, especially in patients with pre-existing heart disease.

Contact your healthcare provider. A single accidental extra dose is unlikely to cause acute toxicity, but should be reported for safety guidance.